Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
1.325
-0.065 (-4.68%)
At close: May 30, 2025, 4:00 PM
1.330
+0.005 (0.38%)
After-hours: May 30, 2025, 6:35 PM EDT
Precigen Revenue
Precigen had revenue of $1.34M in the quarter ending March 31, 2025, with 25.92% growth. This brings the company's revenue in the last twelve months to $4.20M, down -22.76% year-over-year. In the year 2024, Precigen had annual revenue of $3.93M, down -36.95%.
Revenue (ttm)
$4.20M
Revenue Growth
-22.76%
P/S Ratio
87.63
Revenue / Employee
$29,378
Employees
143
Market Cap
389.64M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
Dec 31, 2021 | 14.27M | -17.73M | -55.40% |
Dec 31, 2020 | 31.99M | -58.73M | -64.74% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PGEN News
- 16 days ago - Precigen Reports First Quarter 2025 Financial Results and Business Updates - PRNewsWire
- 6 weeks ago - Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th - PRNewsWire
- 2 months ago - Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Precigen Reports Full Year 2024 Financial Results and Business Updates - PRNewsWire
- 2 months ago - Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th - PRNewsWire
- 3 months ago - Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement - Seeking Alpha
- 3 months ago - FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PRNewsWire
- 4 months ago - Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire